Proteostasis Therapeutics (NASDAQ:PTI) and Orexigen Therapeutics (OTCMKTS:OREXQ) are both small-cap medical companies, but which is the better stock? We will compare the two companies based on the strength of their valuation, analyst recommendations, institutional ownership, dividends, profitability, earnings and risk.
Valuation & Earnings
This table compares Proteostasis Therapeutics and Orexigen Therapeutics’ top-line revenue, earnings per share (EPS) and valuation.
|Gross Revenue||Price/Sales Ratio||Net Income||Earnings Per Share||Price/Earnings Ratio|
|Proteostasis Therapeutics||$5.34 million||48.25||-$59.43 million||($2.34)||-3.00|
|Orexigen Therapeutics||$33.71 million||0.00||-$24.52 million||N/A||N/A|
This table compares Proteostasis Therapeutics and Orexigen Therapeutics’ net margins, return on equity and return on assets.
|Net Margins||Return on Equity||Return on Assets|
This is a summary of current ratings and recommmendations for Proteostasis Therapeutics and Orexigen Therapeutics, as reported by MarketBeat.
|Sell Ratings||Hold Ratings||Buy Ratings||Strong Buy Ratings||Rating Score|
Proteostasis Therapeutics currently has a consensus target price of $14.67, suggesting a potential upside of 108.93%. Given Proteostasis Therapeutics’ higher possible upside, equities analysts clearly believe Proteostasis Therapeutics is more favorable than Orexigen Therapeutics.
Volatility and Risk
Proteostasis Therapeutics has a beta of -3.25, indicating that its share price is 425% less volatile than the S&P 500. Comparatively, Orexigen Therapeutics has a beta of 2.48, indicating that its share price is 148% more volatile than the S&P 500.
Institutional and Insider Ownership
64.6% of Proteostasis Therapeutics shares are held by institutional investors. Comparatively, 0.2% of Orexigen Therapeutics shares are held by institutional investors. 19.8% of Proteostasis Therapeutics shares are held by company insiders. Comparatively, 13.3% of Orexigen Therapeutics shares are held by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company will outperform the market over the long term.
Orexigen Therapeutics beats Proteostasis Therapeutics on 6 of the 11 factors compared between the two stocks.
Proteostasis Therapeutics Company Profile
Proteostasis Therapeutics, Inc., a clinical stage biopharmaceutical company, discovers and develops novel therapeutics to treat cystic fibrosis and other diseases caused by an imbalance in the proteostasis network. Its lead product candidate is PTI-428, an orally bioavailable cystic fibrosis transmembrane conductance regulator modulator belonging to the amplifier class, which is in Phase II study. The company is also involved in developing PTI-801, a corrector molecule; and PTI-808, a potentiator molecule that have been completed Phase I Study. It has a collaboration agreement with Astellas Pharma Inc. Astellas Pharma, Inc. to research and identify therapies targeting the UPR pathway. The company was formerly known as Proteoguard, Inc. and changed its name to Proteostasis Therapeutics, Inc. in September 2007. Proteostasis Therapeutics, Inc. was founded in 2006 and is headquartered in Cambridge, Massachusetts.
Orexigen Therapeutics Company Profile
Orexigen Therapeutics, Inc., a biopharmaceutical company, focuses on the development of pharmaceutical products primarily in the United States, Europe, and South Korea. It offers Contrave for the treatment of obesity. The company also offers Contrave under the Mysimba brand name. Orexigen Therapeutics, Inc. was founded in 2002 and is headquartered in La Jolla, California. On March 12, 2018, Orexigen Therapeutics, Inc., filed a voluntary petition for reorganization under Chapter 11 in the U.S. Bankruptcy Court for the District of Delaware.
Receive News & Ratings for Proteostasis Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Proteostasis Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.